{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan",
            "Single intraarticular dose of 2ml Plasmalyte"
      ],
      "ArmGroupInterventionName": [
            "Biological: Ex- vivo cultured adult allogeneic MSCs",
            "Biological: Plasmalyte-A"
      ],
      "ArmGroupLabel": [
            "Ex- vivo cultured adult allogeneic MSCs",
            "Plasmalyte-A"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01453738"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This trial is planed to study if allogeneic mesenchymal stem cells would be safe and beneficial in osteoarthritis of knee joint. This is a double blind study. Different doses of stem cells will be used in this study."
      ],
      "BriefTitle": [
            "Allogeneic Mesenchymal Stem Cells in Osteoarthritis"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "November 2014"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Osteoarthritis of Knee"
      ],
      "ConditionAncestorId": [
            "D000001168",
            "D000007592",
            "D000009140",
            "D000012216"
      ],
      "ConditionAncestorTerm": [
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteoarthritis",
            "Osteoarthritis of Knee"
      ],
      "ConditionBrowseLeafId": [
            "M12078",
            "M21321",
            "M3628",
            "M9773",
            "M11249",
            "M14197",
            "M5475"
      ],
      "ConditionBrowseLeafName": [
            "Osteoarthritis",
            "Osteoarthritis, Knee",
            "Arthritis",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010003",
            "D000020370"
      ],
      "ConditionMeshTerm": [
            "Osteoarthritis",
            "Osteoarthritis, Knee"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMales or females in the age 40 - 70 years (both inclusive)\nRadiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic criteria.\nHistory of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics.\nSelf-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs.\nPatients who have been on stable medication which may be NSAIDs / Opioid or opiate analgesics, for the past three months.\nFemale patients of childbearing age must be willing to use accepted methods of contraception during the course of the study\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\nPrior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.\nHistory of surgery, or major trauma to the study joint\nArthroscopy on the study joint in the previous 12 months\nSigns of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination\nPatients who had received intraarticular steroids or hyaluronan within the last three months.\nInfections in or around the knee.\nPatients awaiting a replacement knee or hip joint\nPatients with other conditions that cause pain\nPatients with deformity of the knee joint.\nSignificantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices\nPatients with other known rheumatic or inflammatory disease such as rheumatoid arthritis\nOther pathologic lesions on x-rays of knee\nPositive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or RPR\nHistory of Bleeding disorders\nKnown hypersensitivity to Hyaluronan products or animal sera\nFor women of child-bearing potential: positive pregnancy test or lactating [Females who are planning pregnancy within next one year should be excluded]"
      ],
      "EnrollmentCount": [
            "60"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000009883",
            "D000019999"
      ],
      "InterventionAncestorTerm": [
            "Ophthalmic Solutions",
            "Pharmaceutical Solutions"
      ],
      "InterventionArmGroupLabel": [
            "Ex- vivo cultured adult allogeneic MSCs",
            "Plasmalyte-A"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All",
            "PhSol"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals",
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafAsFound": [
            "AKT"
      ],
      "InterventionBrowseLeafId": [
            "M9030",
            "M85407",
            "M11966",
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Hyaluronic Acid",
            "Plasma-lyte 148",
            "Ophthalmic Solutions",
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "high",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan",
            "Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan"
      ],
      "InterventionMeshId": [
            "C000012499"
      ],
      "InterventionMeshTerm": [
            "Plasma-lyte 148"
      ],
      "InterventionName": [
            "Ex- vivo cultured adult allogeneic MSCs",
            "Plasmalyte-A"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Osteoarthritis",
            "Knee",
            "Stem cells",
            "Mesenchymal Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 12, 2016"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "May 11, 2016"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Stempeutics Research Pvt Ltd"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Bangalore",
            "Manipal",
            "Mumbai",
            "Pune",
            "Lucknow"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "India",
            "India",
            "India",
            "India",
            "India"
      ],
      "LocationFacility": [
            "Department of Orthopedics, M. S. Ramaiah Memorial Hospital",
            "Department of Orthopedics, Kasturba Medical College",
            "Seth G. S. Medical College and KEM Hospital",
            "Jehangir Hospital",
            "Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences"
      ],
      "LocationState": [
            "Karnataka",
            "Karnataka",
            "Maharashtra",
            "Maharashtra",
            "Uttar Pradesh"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "560054",
            "576 104",
            "400012",
            "411001",
            "226 014"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "40 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Stempeutics Research Pvt Ltd"
      ],
      "OrgStudyId": [
            "SRPL/OA/09-10/001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences",
            "Department of Orthopedics, Kasturba Medical College",
            "Department of Orthopedics, M. S. Ramaiah Memorial Hospital",
            "Jehangir Hospital",
            "Seth G. S. Medical College and KEM Hospital"
      ],
      "OverallOfficialName": [
            "Vikas Agarwal, MD., DM",
            "Vivek Pandey, MS",
            "Naresh Shetty, MS",
            "Shrikant Wagh, MD",
            "Bhibas Dasgupta, MS"
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Safety evaluation will include assessment of physical examination, periodic monitoring of vital signs (heart rate, respiratory rate, blood pressure and temperature), clinical laboratory investigations (including haematology, serum chemistry, LFT, urine-analysis) and 12-lead ECG recording.\nTolerability: Adverse events monitored using information volunteered by the patients and as observed by the PI will be summarized descriptively by total number of AE(s) and compared between the study arms."
      ],
      "PrimaryOutcomeMeasure": [
            "Number and percentage of patients with adverse events as a measure of safety and tolerability"
      ],
      "PrimaryOutcomeTimeFrame": [
            "2 years"
      ],
      "ReferenceCitation": [
            "Gupta PK, Chullikana A, Rengasamy M, Shetty N, Pandey V, Agarwal V, Wagh SY, Vellotare PK, Damodaran D, Viswanathan P, Thej C, Balasubramanian S, Majumdar AS. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016 Dec 20;18(1):301."
      ],
      "ReferencePMID": [
            "27993154"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score",
            "Change from baseline in WOMAC OA stiffness index",
            "Change from baseline in WOMAC OA composite index",
            "Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)",
            "Change from baseline in radiographic (X-ray) findings of knee",
            "Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI",
            "Change from baseline in arthritis pain scores on the visual analogue scale",
            "Reduction in the intake of analgesic tablets from baseline"
      ],
      "SecondaryOutcomeTimeFrame": [
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "November 2011"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "May 2016"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "October 18, 2011"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "October 13, 2011"
      ],
      "StudyFirstSubmitQCDate": [
            "October 17, 2011"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}